Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention
Authors:
- Jun LiangJLJun Liang
- Ying QianYQYing Qian
- Dan XuDXDan Xu
- Qun YinQYQun Yin
- Hui-Juan PanHPHui-Juan Pan
Open Access
- 30 June 2013
- journal article
- research article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (6) , 3851-3854
Abstract
To explore changes in the serum tumor makers, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC) before and after intervention. Forty patients with NSCLC and 40 healthy individuals undergoing physical examination in our hospital provided the observation and control groups. HIF-1α and VEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observation group before and after intervention and in control group on the day of physical examination, along with serum carcino-embryonic antigen (CEA), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement of life quality in the observation group were also evaluated. The total effective rate and improvement of life quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF-1α and VEGF levels in the control group were lower than that in observation group (p<0.01), but remarkably elevated after intervention (p<0.01). In addition, serum CEA, NSE and SCC levels were apparently lowered by treatment (p<0.01). Serum HIF-1α demonstrated a positive relation with VEGF level (p<0.01) and was inversely related with CEA, NSE and SCC levels (p<0.01). Significant correlations exist between marked increase of serum HIF-1α and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLC patients after intervention.Keywords
This publication has 23 references indexed in Scilit:
- Improving Outcomes in Advanced Lung Cancer : Maintenance Therapy in Non-Small-Cell Lung Carcinoma = تحسين النتائج في سرطان الرئة المتقدم : العلاج المستدام في سرطان الرئة ذي الخلية غير الصغيرةSultan Qaboos University Medical Journal, 2013
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancerOncotarget, 2013
- Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cellsCancer Letters, 2012
- Elevated SP-1 Transcription Factor Expression and Activity Drives Basal and Hypoxia-induced Vascular Endothelial Growth Factor (VEGF) Expression in Non-Small Cell Lung CancerJournal of Biological Chemistry, 2012
- Overexpression of the HIF Hydroxylases PHD1, PHD2, PHD3 and FIH Are Individually and Collectively Unfavorable Prognosticators for NSCLC SurvivalPLOS ONE, 2011
- Interventionell-radiologische Therapien in der pneumologischen OnkologiePneumologie, 2011
- HIF, hypoxia and the role of angiogenesis in non-small cell lung cancerExpert Opinion on Therapeutic Targets, 2010
- Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in MiceJournal of Thoracic Oncology, 2010
- HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell linesJournal of Cancer Research and Clinical Oncology, 2009
- Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancerLung Cancer, 2005